Weight Loss Injections for Free: What the NHS Offers and What It Doesn't

Can you genuinely get weight loss injections for free on the NHS right now?

Yes — but the bar is higher than most people expect. NHS England is rolling out tirzepatide (Mounjaro) through GP practices and specialist services under a phased commissioning plan guided by NICE's appraisal of tirzepatide (TA1026). The first cohort, which opened in June 2025, requires a BMI of 40 or above plus four or more of a specific set of weight-related conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. That's a demanding combination.

A second cohort opened in June 2026, extending eligibility to people with a BMI of 35 to 39.9 who also carry four or more of those same conditions. Further cohorts are planned, with a BMI-40-plus group requiring three conditions expected around March 2027. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, typically 2.5 kg/m² less than the stated figure.

Wegovy (semaglutide injection) is also available on the NHS, but under a different pathway: NICE's TA875 recommendation limits it to specialist weight management services, for a maximum of two years, for adults with at least one weight-related comorbidity and a BMI of 35 or above. Waiting lists for these services are commonly long. Checking whether you meet current criteria is worth doing, but it's honest to say most people enquiring today won't qualify yet. There's a fuller breakdown of free-access routes here if you want to go deeper on eligibility specifics.

If you don't qualify for NHS treatment, what are the legal alternatives?

A question our prescribers hear most weeks goes something like this: "I checked with my GP and I don't meet the NHS criteria, does that mean I have to wait years?" Not necessarily. Private prescriptions through a GPhC-registered online pharmacy are the legal route. The licensed eligibility criteria for private treatment follow the medicines' SmPCs rather than the NHS commissioning thresholds: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, may be suitable. A prescriber still makes that call after reviewing your individual picture.

Private treatment doesn't involve a waiting list in the way NHS specialist services do. Once a consultation is submitted and reviewed, treatment can be in hand within a day. The trade-off is cost: private prescriptions are not subsidised, so the full price of the medicine falls to the patient. A guide to what private treatment actually costs runs through what legitimate prices cover and what drives the variation between providers.

One thing to treat as a hard line: Mounjaro and Wegovy are prescription-only medicines. Any seller offering them without a clinical consultation attached is operating outside UK law. The MHRA's Yellow Card scheme accepts reports of suspect sellers, and the MHRA has seized large volumes of counterfeit pens sold this way. The price saving from an unverified seller is not worth the risk.

Which injection is available on the NHS, and does it match private treatment?

Both Mounjaro and Wegovy are accessible through NHS pathways, but via different routes. Mounjaro, a dual GIP and GLP-1 receptor agonist, is the newer of the two and is now the main medicine being prescribed through GP practices under the phased rollout. Wegovy, a GLP-1 receptor agonist, sits within specialist services. Neither is automatically available to every NHS patient who wants it.

For people comparing the two on results, trial evidence gives a useful steer. In the SURMOUNT-1 trial, tirzepatide produced average body-weight reductions of around 20 to 21 per cent at the highest dose over 72 weeks. STEP 1 reported roughly 15 per cent average reduction with semaglutide 2.4mg over 68 weeks. Head-to-head data from the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, showed greater average weight loss with tirzepatide. Which one suits a specific person is a clinical question, not a ranking exercise. If you'd like a side-by-side look at how the two compare, this page on injection results covers the evidence in detail.

Neither medicine is suitable for everyone. People with a history of medullary thyroid carcinoma, certain gastrointestinal conditions, or those who are pregnant, breastfeeding, or trying to conceive should not take these medicines. A full list of who these injections are not suitable for is covered at this page on contraindications.

What does the private consultation process look like if you want to explore that route?

If NHS treatment isn't currently accessible and private treatment seems worth exploring, the process through a regulated pharmacy is straightforward. At nume, it starts with a free online consultation, no GP referral required. That consultation goes to a GPhC-registered Independent Prescriber: a real clinician who reads your answers the same day, not software running an automatic check. Photo-ID verification and live weight confirmation are part of the process before anything is dispensed.

If the prescriber approves the treatment, orders placed before midday on a working day are dispatched the same day and arrive the next working day via DPD in plain, unbranded packaging. The price includes the consultation, prescription, treatment and delivery in one figure, no extras added at checkout. There are no subscriptions; each repeat order is reviewed clinically again before it goes out.

Understanding the full picture of weight-loss treatment options, including lifestyle support alongside any medicine, is a sensible starting point before any clinical conversation. A guide to which weight thresholds apply for different injections can also help you work out where you'd likely sit before booking a consultation.

If you'd like to find out whether you're clinically suitable for private treatment, you can speak to our prescribers through a free consultation, there's no obligation, and the review is done the same day.